Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.

Aurora Cannabis

Arena Pharmaceuticals

Canopy Growth

HEXO Corp

FSD Pharma

Akerna Corp

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

Village Farms International

cbdMD Inc

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to watch in the upcoming week.

11 Cannabis Stocks Making Moves While Riding the 'Green Wave'

Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) consolidated net revenue of CA$67.8 million ($52.3 million) for the first quarter of fiscal 2021, being up by around CA$300,000 from the fourth quarter of fiscal 2020.

Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results

DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2020, and provided an overview of recent operational highlights.

Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights

Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meeting is expected to take place Q4 2020, where the company will discuss a potential path forward using Zygel to treat Fragile X syndrome patients with FMR1 gene.

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the CONNECT-FX (Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with Fragile X) trial describing the role of FMR1 methylation status in children and adolescents with Fragile X syndrome (FXS) as a correlate to disease severity and as a prognostic biomarker. These data are being presented at the virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting. These data will also be presented as an oral presentation during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session of the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting on Friday, October 23rd, 2020.

Zynerba Pharmaceuticals Presents Data Supporting FMR1 Methylation Status as a Correlate to Fragile X Syndrome Severity at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting

DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster describing data from the Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial further demonstrating the potential for Zygel™ (ZYN002) to improve the core behavioral symptoms of autism when administered in addition to stable standard of care in children and adolescents with moderate-to-severe ASD. These open label data are being presented at the virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CNS) Meeting. These data will also be presented as an oral presentation during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session of the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting on Friday, October 23rd, 2020.

New Data Describing Statistically Significant Results from the Phase 2 BRIGHT Trial in Patients with Autism Spectrum Disorder (ASD) Presented at the Virtual Joint 16th International Child Neurology Congress (ICNC) & 49th Annual Child Neurology Society (CN

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at the virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting. The oral presentations will take place during the “Research Pipeline: New Findings on Diagnostic and Therapeutics” session. The AACAP annual meeting is being held virtually from October 12th through October 24th, 2020. A copy of the slides will be made available on Friday October 23rd at the time of presentation on the Zynerba corporate website at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Oral Presentations at the Virtual American Academy of Child and Adolescent Psychiatry (AACAP) 2020 Annual Meeting

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting. The CNS-ICNA annual meeting is being held virtually from October 12th through October 23rd, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation on Monday October 12th at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting

Pivotal results from Phase 3 clinical trials of Zygel for the treatment of FX Syndrome didn’t meet endpoints, but a significant discovery was made.

Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients

Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%

Making The Case For Zynerba Pharmaceuticals

DEVON, Pa., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems.

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully Methylated FMR1 Gene -

Zynerba Pharmaceuticals Provides Update on Recent Milestones

DEVON, Pa., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will participate in two upcoming virtual investor conferences. Mr. Anido will present a company overview at the HC Wainwright Virtual 22nd Annual Healthcare Conference on Monday September 14, 2020 at 3:30PM EDT. He will also present at the 2020 Cantor Global Virtual Healthcare Conference on Tuesday September 15, 2020 at 1:20PM EDT. Both meetings are being held virtually, and live webcasts of the presentations will be accessible on the Investor Relations page of http://www.zynerba.com.

Zynerba Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

Amplify Seymour Cannabis ETF

GrowGeneration Corp

GW Pharmaceuticals

Innovative Industrial Properties

Amplify Alternative Harvest ETF

Global X Cannabis ETF

Scotts Miracle-Gro

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Pure Cannabis ETF 

Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.

Pharma Medical Cannabis More Robust And Resilient (Podcast Transcript)

DEVON, Pa., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2020, and provided an overview of recent operational highlights.

Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights

DEVON, Pa., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the virtual 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Wednesday, August 12, 2020 at 4:30PM EDT. This meeting is being held virtually, and a live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.

Zynerba Pharmaceuticals to Present at the Virtual 40th Annual Canaccord Genuity Growth Conference

Pharma Medical Cannabis More Robust And Resilient (Podcast)

Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.

Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - - New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes -

Zynerba Pharmaceuticals to Present an Update on the Zygel™ Development Program at the 17th NFXF International Fragile X Conference Research Roundup

IVERIC bio Inc

Rubius Therapeutics Inc

Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma

Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.

Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares retreated to their lowest level since early April following a clinical readout from the company.

Synthetic Cannabinoid Drug Maker Zynerba Plummets 50%

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has disclosed that its cannabis-based gel did not see statistically significant results from its most recent study.

News for Zynerba Pharmaceuticals Stock (ZYNE)